Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Rifaximin in Minimal Hepatic Encephalopathy

This study has been completed.
Sponsor:
Collaborator:
Salix Pharmaceuticals
Information provided by (Responsible Party):
Jasmohan Bajaj, Hunter Holmes Mcguire Veteran Affairs Medical Center
ClinicalTrials.gov Identifier:
NCT01069133
First received: February 16, 2010
Last updated: December 10, 2012
Last verified: December 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: December 2012
  Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
No publications provided by Hunter Holmes Mcguire Veteran Affairs Medical Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):